Related Experiment Video
Updated: Jul 16, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally
Caglayan Selenge Beduk Esen1, Sukran Celikarslan2, Duygu Sezen2
1Department of Radiation Oncology, American Hospital, Istanbul 34365, Türkiye.
Cancers
|July 15, 2026
Summary
Consolidative hypofractionated thoracic radiotherapy (RT) after chemoimmunotherapy shows promising safety and low failure rates for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). This approach warrants further investigation in prospective trials.
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Surgery
Background:
- Unresectable locally advanced non-small cell lung cancer (LA-NSCLC) presents a significant treatment challenge.
- Induction chemoimmunotherapy followed by consolidative thoracic radiotherapy (RT) is an emerging treatment strategy.
- Evaluating the safety and efficacy of hypofractionated RT in this setting is crucial.
Purpose of the Study:
- To assess the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT).
- To evaluate outcomes in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) treated with induction chemoimmunotherapy followed by RT.
- To determine local recurrence (LR), regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and toxicity.
Main Methods:
- Retrospective analysis of 34 patients with unresectable LA-NSCLC treated between 2019 and 2025.
- Patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT (median 52.5 Gy in 15 fractions).
- Endpoints included LR, RR, DM, OS, PFS, and treatment-related toxicity.
Main Results:
- The 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively; no isolated local recurrences occurred.
- 1- and 2-year OS rates were 86% and 81%; PFS rates were 76% and 54%, respectively.
- No grade 4-5 RT-related toxicity was observed; one grade 5 immune-related pneumonitis occurred.
Conclusions:
- Consolidative hypofractionated thoracic RT following induction chemoimmunotherapy is feasible in LA-NSCLC.
- This treatment strategy demonstrated favorable survival outcomes and manageable toxicity.
- Further prospective investigation is warranted to confirm these findings.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...